cefaclor anhydrous has been researched along with Osteomyelitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, T; Hashimoto, S; Tanaka, H; Tsugawa, K; Watanabe, S | 1 |
| Bucholz, RW; Kusmiesz, H; Nelson, JD; Shelton, S | 1 |
2 other study(ies) available for cefaclor anhydrous and Osteomyelitis
| Article | Year |
|---|---|
Osteomyelitis-related glomerulonephritis with myeloperoxidase-antineutrophil cytoplasmic antibody positivity.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Cefaclor; Cefazolin; Child; Female; Glomerulonephritis; Humans; Magnetic Resonance Imaging; Osteomyelitis; Peroxidase; Prednisolone; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome | 2020 |
Benefits and risks of sequential parenteral--oral cephalosporin therapy for suppurative bone and joint infections.
Topics: Acute Disease; Administration, Oral; Arthritis, Infectious; Bacterial Infections; Cefaclor; Cefamandole; Cefuroxime; Cephalexin; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Parenteral; Male; Osteoarthritis; Osteomyelitis; Suppuration | 1982 |